Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Eisai/Helsinn Healthcare's Aloxi's marketing message ("Better in acute, better in delayed") is rated the most influential by oncologists in the chemotherapy-induced nausea and vomiting drug market. Oncologists accurately identified Aloxi's messages with the brand, highlighting the strength of the Aloxi messaging campaign.

According to the new report entitled Brands & Strategies: Chemotherapy-Induced Nausea and Vomiting, U.S. physicians rate Aloxi higher than Merck's Emend in terms of top-of-mind therapy despite Aloxi and Emend launching in the same year in the United States. Emend scored low in terms of brand recognition with less than 20 percent of oncologists identifying the correct messages associated with the brand. Surveyed oncologists rate Emend's marketing messages ("More complete prevention comes from two directions" and "Used in more than 2.7 million chemotherapy cycles over 5 years") in the bottom three most influential messages, with the latter being the least identifiable message. Despite this, both Emend and Aloxi are forecasted to dominate the chemotherapy-induced nausea and vomiting market in 2012.

"Promotional spending on chemotherapy-induced nausea and vomiting drug therapies in the United States is relatively low compared to other therapeutic areas," said Marcus Hoyle, analyst at Decision Resources. "In 2007 $61 million was spent by the leading competitors (Merck, MGI Pharma/Eisai, Roche and Sanofi-Aventis) in the United States to promote their respective brands."

About Brands & Strategies

The Brands & Strategies report series from Decision Resources reveals what it takes to be successful in a pharmaceutical market. It offers the most comprehensive commercial analysis of the brands and strategies of competing companies so they can better position themselves in a market and plan future strategy based on what competitors are doing. Brands & Strategies is the first and only report series to bring together all the competitive information elements pharma companies need to make informed decisions about their brands and next-steps.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Heather Hilty              Elizabeth Marshall   Decision Resources         Decision Resources, Inc.   781-296-2536               781-296-2563   hhilty@dresources.com      emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

Contact: Heather Hilty of Decision Resources, +1-781-296-2536,
hhilty@dresources.com; or Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Modest Drug Pipeline and Significant Generic Erosion Will Decrease the Bipolar Depression Drug Market by More Than $1 Billion Through 2017

View Now